Opus Genetics (IRD) Change in Receivables (2022 - 2026)
Opus Genetics (IRD) reported Change in Receivables of -$264000.0 for Q1 2026, up 45.34% year-over-year from -$181641.0 in Q1 2025, and up 71.34% quarter-over-quarter from -$921000.0 in Q4 2025.
Opus Genetics (IRD) Change in Receivables (2022 - 2026) Analysis & Trends
Opus Genetics (IRD) has 5 years of Change in Receivables data on file, last reported at -$264000.0 in Q1 2026.
- Change in Receivables for Q1 2026 came in at -$264000.0, up 45.34% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.3 million (down 216.7% YoY), and the FY2025 annual result was -$1.6 million, down 159.46% from the prior year.
- Change in Receivables rose to -$264000.0 in Q1 2026 per IRD's latest filing, from -$921000.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $10.0 million in Q3 2023 and troughed at -$9.2 million in Q4 2023.
- A 5-year average of $123642.9 and a median of $27500.0 in 2025 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2023 and 2025: Change in Receivables sank 809.24% in 2023, then soared 156.36% in 2025.
- A 5-year view of Change in Receivables shows it stood at $1.3 million in 2022, then slumped by 809.24% to -$9.2 million in 2023, then soared by 118.53% to $1.7 million in 2024, then plunged by 153.99% to -$921000.0 in 2025, then surged by 71.34% to -$264000.0 in 2026.
- Business Quant data shows IRD's Change in Receivables at -$264000.0 in Q1 2026, -$921000.0 in Q4 2025, and -$483000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Opus Genetics | 355.39 Mn | 295.43 Mn | - | -264,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -264,000.00 |
| Mar 31, 2026 | -264,000.00 |
| Dec 31, 2025 | -921,000.00 |
| Dec 31, 2025 | -921,000.00 |
| Sep 30, 2025 | -483,000.00 |
| Sep 30, 2025 | -483,000.00 |
| Jun 30, 2025 | 319,000.00 |
| Jun 30, 2025 | 319,000.00 |
| Mar 31, 2025 | -483,000.00 |
| Mar 31, 2025 | -483,000.00 |
| Dec 31, 2024 | 1.71 Mn |
| Dec 31, 2024 | 1.71 Mn |
| Sep 30, 2024 | 499,000.00 |
| Sep 30, 2024 | 499,000.00 |
| Jun 30, 2024 | -566,000.00 |
| Jun 30, 2024 | -566,000.00 |
| Mar 31, 2024 | 998,000.00 |
| Mar 31, 2024 | 998,000.00 |
| Dec 31, 2023 | -9.21 Mn |
| Dec 31, 2023 | -9.21 Mn |